A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx).
暂无分享,去创建一个
K. Ahrar | E. Jonasch | C. Wood | P. Sharma | C. Ng | Jianjun Gao | J. Blando | Hao Zhao | J. Allison | S. Matin | Yu Shen | J. Karam | M. Campbell | A. Shah | S. Basu | A. Zurita | N. Tannir | P. Rao | L. Vence | R. Tidwell | Sreyashi Basu | Padmanee Sharma